Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03699618 · ClinicalTrials.gov registry record
Anti-VEGF Therapy for Subfoveal Hemorrhage in Patients With Neovascular Age-Related Macular Degeneration
A clinical trial, sponsored by Johns Hopkins University.
- Terminated
- Registry status
- 1
- Enrollment target
NCT03699618: Clinical Trial study, sponsored by Johns Hopkins University.
NCT03699618 is a clinical trial that was terminated before completion, run by Johns Hopkins University. The registered enrollment target is 1 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03699618 was terminated before completion, sponsored by Johns Hopkins University.
- TERMINATED
- Registry status
- 1 participants
- Enrollment target
Study Summary
This study will define the limits of subretinal hemorrhage parameters that are consistent with a good visual outcome with aggressive anti-VEGF treatment in patients with neovascular age-related macular degeneration (NVAMD).
Primary Outcome
Correlation between baseline SFH characteristics measured on Spectralis SD-OCT (size and thickness of SFH, and shortest distance between border of SFH and fovea) and good visual acuity outcome (≥20/50) after controlling for baseline visual acuity in patients receiving monthly IVT anti-VEGF injections using pearson or spearman correlation coefficients based on normality of the data.
Interventions
- DRUG Anti-VEGF
- OTHER Hemorrhage displacement + Anti-VEGF
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 1 participants |
| Start Date | 2019-05-29 |
| Est. Completion | 2020-01-06 |
Why NCT03699618 stopped before completion
NCT03699618 is an observational study that tracks outcomes without assigning an intervention. The registry caps enrollment at 1 participants, a relatively small participant target.
The record links to 0 conditions, and to 2 interventions - of which Anti-VEGF is the first listed.
NCT03699618 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT03699618 about?
NCT03699618 is a clinical study titled "Anti-VEGF Therapy for Subfoveal Hemorrhage in Patients With Neovascular Age-Related Macular Degeneration". This study will define the limits of subretinal hemorrhage parameters that are consistent with a good visual outcome with aggressive anti-VEGF treatment in patients with neovascular age-related macular degeneration (NVAMD).
What is the current status of trial NCT03699618?
This trial is currently terminated. The enrollment target is 1 participants. The study started on 2019-05-29. Estimated completion is 2020-01-06.
What interventions are being tested in trial NCT03699618?
The interventions under investigation include: Anti-VEGF (DRUG), Hemorrhage displacement + Anti-VEGF (OTHER).
Who is sponsoring clinical trial NCT03699618?
This trial is sponsored by Johns Hopkins University, which has 1,448 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI